Global Rhabdomyosarcoma Clinical Trials Research Trends- Analysis of Trial Phases, Markets, Recruitment, Trial Types, Enrolment, Intervention and Companies

Global Rhabdomyosarcoma Clinical Trials Research Trends- Analysis of Trial Phases, Markets, Recruitment, Trial Types, Enrolment, Intervention and Companies

  • August 2017 •
  • 87 pages •
  • Report ID: 5139476 •
  • Format: PDF
Rhabdomyosarcoma clinical trials report from VPA Research provides comprehensive analysis and trends in global Rhabdomyosarcoma disease clinical trials. The research work analyzes the evolution of Rhabdomyosarcoma clinical trial trends across countries and regions.

The report focuses on drugs and therapies being evaluated for Rhabdomyosarcoma treatment in active clinical development phases including phase 1, phase 2, phase 3 and phase 4 clinical trials. The report also provides trials information by region, key countries, phases, trial status and sponsor types.

Our experienced database team dynamically updates the clinical trials data from several sources including Clinical trial registries, conferences, journals and company releases etc. Further, data is presented in user friendly manner to enable readers quick access to Rhabdomyosarcoma clinical trials.

Scope of the Report-
- Number of Rhabdomyosarcoma clinical trials across regions- Asia and Oceania, Europe, Middle East Africa and Americas
- Trial information by Phase and Subjects recruited
- Trial information by status, type, sponsor type
- Drugs used for treatment of Rhabdomyosarcoma
- Both observational and interventional trials analyzed
- Success rates of trials are analyzed
- Trends in enrollment over the past ten years identified
- Leading sponsors of Rhabdomyosarcoma clinical trials worldwide are listed

Reasons to Buy
- Track competition and design competitive advantages
- Identify right partners to associate with for further research
- Evaluate potential opportunities available in further clinical trials of the disease
- Formulate business development strategies through success rates of clinical trials
- Identify quick markets for recruiting subjects based on trials count by each market

Executive Summary

Rhabdomyosarcoma is one of the most common types of soft tissue sarcoma found both in children and young adults. It can originate from any part of the body with muscle tissues like skeletal or smooth muscles. Common site are arms and legs, reproductive organs, head and neck.

Globally, 40 countries participated in clinical trials. Of this, the US leads the list of countries with a participation in 139 trials, Canada (29 trials) and Germany (25 trials).

Some of the key drugs approved for Rhabdomyosarcoma by FDA include-
- Actinomycin (Dactinomycin)
- Vincristine (Leurocristine Sulfate/ LCR/VCR)
- Cyclophosphamide (CPM/CTX/CYT)
Loading...

We are very sorry, but an error occurred.
Please contact support@reportbuyer.com if the problem remains.